Resverlogix Corp. ("Resverlogix" or the "Company") announced the recent publication of an article titled: “Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study”, in the high-impact, peer-reviewed Cardiovascular Diabetology. Publication Highlights include: BETonMACE was the first, and only, Phase 3 clinical trial to evaluate the cardiovascular efficacy and safety of a BET protein inhibitor. pabetalone treatment, in a pre-specified analysis, was associated with a 41% hazard reduction for first hospitalization for heart failure compared to placebo (p=0.03) with qualitative evidence of an early and progressive separation in events between the two groups. When total hospitalizations for heart failure were analyzed, apabetalone treatment demonstrated a significant 53% hazard reduction (p=0.01). The combination of either first hospital admission for heart failure or cardiovascular death occurred less frequently in apabetalone than placebo-treated patients (28% hazard reduction, p=0.04). Following 24 weeks of apabetalone treatment, a statistically significant increase in high-density lipoprotein (HDL) (15.4%; p<0.0001) and decrease in alkaline phosphatase (ALP) (-8.31%; p<0.0001) was observed compared to the placebo group. These findings contribute to apabetalone’s beneficial effect on cardiovascular outcomes observed in BETonMACE. Despite current standard of care treatment options, patients with diabetes and ACS have a high risk of experiencing subsequent cardiovascular events, including those related to congestive heart failure. This prespecified analysis, illustrated that treatment with apabetalone following an ACS was associated with a lower incidence of hospital admission for heart failure. This finding provides the rationale to further explore apabetalone’s effect on HHF and highlights a potential new therapeutic strategy to benefit these high-risk patients.